Association of Intestinal Disorders with Parkinson’s Disease and Alzheimer’s Disease: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are the most common neurodegenerative disorders, with an overall global incidence of 40 million. Many studies have revealed the association of intestinal disorders and bacterial infections with PD, but few studies have found such a relationship with AD. In this meta-analysis, related articles published up to September 2018 were searched in PubMed. Of the 2121 related articles screened initially, 56 were found to be eligible. Data on the risks of PD and AD due to five intestinal disorders and infection with Helicobacter pylori, as a representative intestinal microbe, were obtained, and a fixed- or random-effects model was used to pool the odds ratios (ORs) with 95% confidence interval (CIs) from individual studies. The combined OR for all types of intestinal disorders with an increased risk of PD was 3.36 (95% CI: 2.70–4.17). The ORs for each category were as follows: constipation, 4.05 (95% CI, 3.24–5.06); inflammatory bowel disease (IBD), 1.16 (95% CI, 0.89–1.52); irritable bowel syndrome (IBS), 1.75 (95% CI, 0.55–5.56); small intestinal bacterial overgrowth, 5.15 (95% CI, 3.33–7.96); and diarrhea, 1.27 (95% CI, 0.28–5.75). The combined OR of all types of intestinal disorders with an increased risk of AD was 1.52 (95% CI, 1.09–2.13). The ORs for IBS and IBD were 1.42 (95% CI, 1.02–1.99) and 2.40 (95% CI, 1.00–5.76), respectively. The risk estimates of H. pylori infection in PD and AD patients were as follows: OR, 1.65 (95% CI, 1.43–1.91) and OR, 1.40 (95% CI, 1.12–1.76), respectively. These findings suggest that PD and AD are significantly associated with intestinal disorders. The negative roles of H. pylori in the development of PD or AD should be evaluated to shed new light on the diagnosis and treatment of PD and AD. National governments should periodically inspect the intestinal condition of residents and extend health plans to improve intestinal health to prevent potential neurological disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
Gastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016
Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O. R., Hamidi, G. A., & Salami, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00256 · Cited by 946
Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z.-Y., Roybon, L., Melki, R., & Li, J.-Y. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1343-6 · Cited by 925
The Gut Microbiota and Alzheimer’s Disease
Jiang, C., Li, G., Huang, P., Liu, Z., & Zhao, B. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161141 · Cited by 852
The Gut Microbiome and the Brain
Galland, L. (2014) · Journal of Medicinal Food · doi:10.1089/jmf.2014.7000 · Cited by 648
Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Klingelhoefer, L., & Reichmann, H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.197 · Cited by 598
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588
Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies
Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., & de Bernard, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055375 · Cited by 585
Brain-Gut-Microbiota Axis in Parkinson’s Disease
Mulak, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10609 · Cited by 583
Chen, S. G., Stribinskis, V., Rane, M. J., Demuth, D. R., Gozal, E., Roberts, A. M., Jagadapillai, R., Liu, R., Choe, K., Shivakumar, B., et al. (2016) · Scientific Reports · doi:10.1038/srep34477 · Cited by 463
Structural changes in the gut microbiome of constipated patients
Zhu, L., Liu, W., Alkhouri, R., Baker, R. D., Bard, J. E., Quigley, E. M., & Baker, S. S. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00082.2014 · Cited by 381
The role of small intestinal bacterial overgrowth in Parkinson's disease
Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25522 · Cited by 344
Nho, K., Kueider‐Paisley, A., MahmoudianDehkordi, S., Arnold, M., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., Kastenmüller, G., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.012 · Cited by 343
Small intestinal bacterial overgrowth in Parkinson's disease
Tan, A. H., Mahadeva, S., Thalha, A. M., Gibson, P. R., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., Tan, C. T., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.019 · Cited by 274
Irritable bowel syndrome, the microbiota and the gut-brain axis
Raskov, H., Burcharth, J., Pommergaard, H.-C., & Rosenberg, J. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1218585 · Cited by 243
α-Synuclein in gut endocrine cells and its implications for Parkinson’s disease
Chandra, R., Hiniker, A., Kuo, Y.-M., Nussbaum, R. L., & Liddle, R. A. (2017) · JCI Insight · doi:10.1172/jci.insight.92295 · Cited by 236
Constipation preceding Parkinson's disease: a systematic review and meta-analysis
Adams-Carr, K. L., Bestwick, J. P., Shribman, S., Lees, A., Schrag, A., & Noyce, A. J. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311680 · Cited by 228
Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota
Noor, S. O., Ridgway, K., Scovell, L., Kemsley, E. K., Lund, E. K., Jamieson, C., Johnson, I. T., & Narbad, A. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-134 · Cited by 227
Bouhnik, Y., Alain, S., Attar, A., Flourié, B., Raskine, L., Sanson-Le Pors, M. J., & Rambaud, J.-C. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01016.x · Cited by 199
Mertsalmi, T. H., Aho, V. T. E., Pereira, P. A. B., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2017) · European Journal of Neurology · doi:10.1111/ene.13398 · Cited by 153
Gastrointestinal Dysfunctions in Parkinson’s Disease: Symptoms and Treatments
Poirier, A.-A., Aubé, B., Côté, M., Morin, N., Di Paolo, T., & Soulet, D. (2016) · Parkinson s Disease · doi:10.1155/2016/6762528 · Cited by 130
Huang, H.-K., Wang, J.-H., Lei, W.-Y., Chen, C.-L., Chang, C.-Y., & Liou, L.-S. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.11.331 · Cited by 106
Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson’s Disease
McGee, D. J., Lu, X.-H., & Disbrow, E. A. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181327 · Cited by 86
Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson's disease
Niu, X.-L., Liu, L., Song, Z.-X., Li, Q., Wang, Z.-H., Zhang, J.-L., & Li, H.-H. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1612-8 · Cited by 64
Cited by
Advancing human gut microbiota research by considering gut transit time
Procházková, N., Falony, G., Dragsted, L. O., Licht, T. R., Raes, J., & Roager, H. M. (2023) · Gut · doi:10.1136/gutjnl-2022-328166 · Cited by 308
The Impact of Disease Comorbidities in Alzheimer’s Disease
Santiago, J. A., & Potashkin, J. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.631770 · Cited by 259
Borghammer, P. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202481 · Cited by 259
A review of studies on gut microbiota and levodopa metabolism
Zhong, Z., Ye, M., & Yan, F. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1046910 · Cited by 31
The endocannabinoid system: a bridge between alzheimer’s disease and gut microbiota
Bisogno, T., Lauritano, A., & Piscitelli, F. (2021) · Life · doi:10.3390/life11090934 · Cited by 16
Metadata
- Authors
- Fu, P., Gao, M., & Yung, K. K. L.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-12-26
- Volume
- 11
- Issue
- 3
- Pages
- 395-405
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2998620289
- Cited by
- 146
- References
- 29
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.